# Evaluation of Vepoloxamer in Chronic Heart Failure

> **NCT02596477** · PHASE2 · TERMINATED · sponsor: **Mast Therapeutics, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Chronic Heart Failure

## Interventions

- **DRUG:** Vepoloxamer
- **OTHER:** 5% dextrose in water

## Key facts

- **NCT ID:** NCT02596477
- **Lead sponsor:** Mast Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2016-10
- **Final completion:** —
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Terminated for administrative reasons not related to safety or efficacy
- **Last updated:** 2016-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02596477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02596477, "Evaluation of Vepoloxamer in Chronic Heart Failure". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02596477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*